BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24936741)

  • 1. Age-related toxicity in patients with rhabdomyosarcoma: a report from the children's oncology group.
    Altaf S; Enders F; Lyden E; Donaldson SS; Rodeberg D; Arndt C
    J Pediatr Hematol Oncol; 2014 Nov; 36(8):599-604. PubMed ID: 24936741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
    Gupta AA; Anderson JR; Pappo AS; Spunt SL; Dasgupta R; Indelicato DJ; Hawkins DS
    Cancer; 2012 Feb; 118(4):1130-7. PubMed ID: 21761400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide.
    Arndt C; Hawkins D; Anderson JR; Breitfeld P; Womer R; Meyer W
    J Clin Oncol; 2004 May; 22(10):1894-901. PubMed ID: 15143082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
    J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group.
    Langholz B; Skolnik JM; Barrett JS; Renbarger J; Seibel NL; Zajicek A; Arndt CA
    Pediatr Blood Cancer; 2011 Aug; 57(2):252-7. PubMed ID: 21671362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol.
    Casanova M; Ferrari A; Bisogno G; Merks JH; De Salvo GL; Meazza C; Tettoni K; Provenzi M; Mazzarino I; Carli M
    Cancer; 2004 Oct; 101(7):1664-71. PubMed ID: 15378498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis.
    Kojima Y; Hashimoto K; Ando M; Yonemori K; Yamamoto H; Kodaira M; Yunokawa M; Shimizu C; Tamura K; Hosono A; Makimoto A; Fujiwara Y
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):391-7. PubMed ID: 22806306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
    Pappo AS; Lyden E; Breitfeld P; Donaldson SS; Wiener E; Parham D; Crews KR; Houghton P; Meyer WH;
    J Clin Oncol; 2007 Feb; 25(4):362-9. PubMed ID: 17264331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
    J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
    Ruymann FB; Vietti T; Gehan E; Wiener E; Wharam M; Newton WA; Maurer H
    J Pediatr Hematol Oncol; 1995 Nov; 17(4):331-7. PubMed ID: 7583389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan AA; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
    J Clin Oncol; 2014 Nov; 32(31):3547-52. PubMed ID: 25267746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
    Spunt SL; Smith LM; Ruymann FB; Qualman SJ; Donaldson SS; Rodeberg DA; Anderson JR; Crist WM; Link MP
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6072-9. PubMed ID: 15447992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of intensified chemotherapy in children with advanced rhabdomyosarcoma (clinical groups III and IV). The Intergroup Rhabdomyosarcoma Study (IRS) Committee of the Cancer and Leukemia Group B Children's Cancer Study Group, Southwest Oncology Group.
    Raney RB; Gehan EA; Maurer HM; Newton WA; Ragab AH; Ruymann FB; Sutow WW; Tefft M
    Cancer Clin Trials; 1979; 2(1):19-28. PubMed ID: 391431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
    Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study.
    Mason SL; Grant IA; Elliott J; Cripps P; Blackwood L
    J Small Anim Pract; 2014 Aug; 55(8):391-8. PubMed ID: 24920169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
    Casey DL; Chi YY; Donaldson SS; Hawkins DS; Tian J; Arndt CA; Rodeberg DA; Routh JC; Lautz TB; Gupta AA; Yock TI; Wolden SL
    Cancer; 2019 Sep; 125(18):3242-3248. PubMed ID: 31174239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
    Arndt CA; Stoner JA; Hawkins DS; Rodeberg DA; Hayes-Jordan AA; Paidas CN; Parham DM; Teot LA; Wharam MD; Breneman JC; Donaldson SS; Anderson JR; Meyer WH
    J Clin Oncol; 2009 Nov; 27(31):5182-8. PubMed ID: 19770373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
    Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
    J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
    J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center.
    Ortega JA; Donaldson SS; Ivy SP; Pappo A; Maurer HM
    Cancer; 1997 Jun; 79(12):2435-9. PubMed ID: 9191535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.